What is the market's earnings forecast for ANI Pharmaceuticals next quarter?

What is the revenue and EPS growth rate for ANI Pharmaceuticals year over year?

What is ANI Pharmaceuticals's latest dividend and current dividend yield?

Did ANI Pharmaceuticals beat or miss consensus estimates last quarter?

What guidance did ANI Pharmaceuticals's management provide for the next earnings period?

What were the key takeaways from ANI Pharmaceuticals’s earnings call?

What is ANI Pharmaceuticals's gross profit margin?

What factors drove the changes in ANI Pharmaceuticals's revenue and profit?

- **Revenue Growth**: 2025 total revenue up 44% to $883.4M; 2026 guided for $1.055B-$1.115B (19-26% growth)
- **Cortrophin Expansion**: 2026 sales force expansion targeting 55-65% growth; 2025 gout utilization at 15% of volumes
- **Generics Cash Flow**: 2025 generics revenue up 28% to $384.1M; 10-15 launches/year
- **Financial Targets**: 2026 EBITDA $275M-$290M (20-26% growth); rare disease to account for 60% of revenue
- **Risk Points**: Royalty rate step-up (28% blended rate) impacting margins; Q1 2026 Cortrophin seasonality

**【CEO Summary Section】**
- **2025 Performance**: Total revenue grew 44% YoY to $883.4M, with adjusted non-GAAP EBITDA up 47% to $229.8M. Cortrophin Gel revenue surged 76% YoY to $347.8M, driven by expansion into underpenetrated rare disease indications.
- **2026 Strategic Priorities**: 
  1. **Rare Disease Growth**: Cortrophin Gel expected to grow 55-65% YoY, targeting acute gouty arthritis flares with a new 90-person sales force. 
  2. **Generics Execution**: Maintain 10-15 launches/year, with 2025 generics revenue up 28% to $384.1M.
  3. **Capital Allocation**: Invest in rare disease expansion while maintaining disciplined leverage (2.7x gross, 1.5x net at end-2025).
- **2026 Outlook**: Guided for $1.055B-$1.115B revenue (19-26% growth), with rare disease accounting for ~60% of total revenue.

**【CFO Financial Commentary】**
- **Q4 2025 Results**: 
  - Total revenue: $247.1M (30% YoY growth)
  - Cortrophin Gel: $111.4M (88% YoY growth)
  - Generics: $100.8M (28% YoY growth)
- **Margins**: 
  - Non-GAAP gross margin: 59.6% (down 400bps YoY due to royalty-bearing products)
  - Adjusted non-GAAP EPS: $2.33 (37% YoY growth)
- **2026 Guidance**: 
  - Cortrophin Gel: $540M-$575M (55-65% growth)
  - EBITDA: $275M-$290M (20-26% growth)
  - Royalty rate: ~28% (blended rate)

**【Q&A Highlights】**
- **Gout Expansion**: 90-person sales force to launch mid-2026, targeting 7,000 primary care/podiatry HCPs. Q3/Q4 2026 will see initial impact, with full productivity in 2027.
- **Operating Leverage**: 2026 OpEx increase of ~$50M (mostly sales force) offset by EBITDA margin stability. 2027+ will see operating leverage benefits.
- **Patient Access**: ILUVIEN specialty pharmacy workflow adoption growing; 2026 guidance excludes patient assistance program funding.
- **Gross Margin**: Royalty rate step-up in 2025 (highest tier) will weigh on margins, but 2026 blended rate remains ~28%.

ANI Pharmaceuticals, Inc. (ANIP) Q4 2025 Earnings Call Transcript

- **Record Growth**: Q3 2025 revenue up 54% YoY, driven by 93.8% surge in Cortrophin Gel to $101.9M.
- **Guidance Raise**: 2025 net revenue target $854-873M (+39-42%), Cortrophin Gel forecast $347-352M (+75-78%).
- **Generics Momentum**: Low 20% growth for 2025, though Q4 may dip due to competitive pressure.
- **ILUVIEN Reset**: 2026 focus on Medicare access and new label adoption, with 10x addressable patient potential.
- **Financial Strength**: $262.6M cash, 1.7x net leverage, and 59.2% adjusted EBITDA margin.

**【CEO Summary Section】**
- **Q3 2025 Performance**: Total revenue grew 54% YoY ($227.8M), with 46% organic growth. Adjusted EBITDA increased 70% to $59.6M. Cortrophin Gel net revenue reached $101.9M, up 93.8% YoY, driven by new patient starts and expanded sales force.
- **2025 Guidance Update**: Full-year net revenue expected to rise 39-42% to $854-873M. Cortrophin Gel forecasted at $347-352M (75-78% growth). Generics growth in low 20% range, though Q4 may dip due to competitive entrants.
- **Strategic Focus**: Rare Disease remains top priority. ILUVIEN faces Medicare access challenges but shows potential for 2026 growth with new label adoption and specialty pharmacy pathways.

**【CFO Financial Commentary】**
- **Q3 Financials**: GAAP net revenue $227.8M (53.6% YoY). Rare Disease segment contributed $118.5M, with Generics at $94.4M. Adjusted EBITDA margin 59.2%, down 63bps due to partnered generic product mix.
- **Cash Flow & Balance Sheet**: $262.6M in unrestricted cash. Full-year 2025 EBITDA guidance raised to $221-228M. Gross leverage 3x, net leverage 1.7x trailing EBITDA.
- **Generics Outlook**: Low 20% growth for 2025, but Q4 expected to decline due to competitive pressure on a key partnered product.

**【Q&A Highlights】**
- **Cortrophin Growth Drivers**: 42% sequential increase in ophthalmology volume. Prefilled syringe adoption at 70% of new cases. Addressable patient populations (e.g., acute gouty arthritis: 285K) underpenetrated, with half of prescribers new to ACTH.
- **Generics Challenges**: Q4 dip in Generics due to competitive entrants, but long-term pipeline remains strong.
- **ILUVIEN Strategy**: 2026 focus on peer-to-peer education, Medicare Part D access via specialty pharmacy, and NEW DAY study dissemination.
- **Sales Force Expansion**: ROI validated by record new patient starts. Pulmonology and neurology show growth potential.
- **Durability of Cortrophin**: Patents extend to 2040s; porcine-derived formulation poses high generic entry barriers.

ANI Pharmaceuticals, Inc. (ANIP) Q3 2025 Earnings Call Transcript

- **Revenue Surge**: Q2 revenue up 53% YoY to $211.4 million, with Cortrophin Gel driving 66% growth to $81.6 million. 2025 guidance raised to $818-$843 million.
- **Cortrophin Momentum**: 70% of new cases use prefilled syringe; ophthalmology volumes rose 33% QoQ. ACTH market projected to grow 36% to $933 million in 2025.
- **Retina Challenges**: Medicare access cuts 2025 retina guidance to $87-$93 million. NEW DAY trial data may expand ILUVIEN use but no near-term impact.
- **Generics Strength**: 22% YoY growth in Generics, but H2 moderation expected. Gross margin improved to 64.9%, targeting 63%-64% for 2025.
- **Balance Sheet**: $217.8 million cash, net leverage 2.2x. Focus on Rare Disease expansion and U.S. manufacturing efficiency.

**【CEO Summary Section】**
- **Record Q2 Performance**: Total net revenue reached $211.4 million, up 53% YoY, driven by 66% growth in Cortrophin Gel to $81.6 million. Adjusted non-GAAP EBITDA was $54.1 million, and EPS was $1.80.
- **Updated 2025 Guidance**: Total revenue raised to $818-$843 million (33%-37% growth), with Cortrophin Gel expected to reach $322-$329 million (63%-66% growth). Retina franchise guidance lowered to $87-$93 million due to Medicare access challenges.
- **Sales Team Expansion**: Portfolio sales team expanded from 52 to 70 members, leading to 54% QoQ growth in Cortrophin Gel. Prefilled syringe adoption reached 70% of new cases initiated.
- **Market Growth**: ACTH market projected to grow 36% to $933 million in 2025, with Cortrophin Gel capturing 57% of total company revenue in H2 2025. Over 50% of prescribers are new to ACTH therapy.

**【CFO Financial Commentary】**
- **Q2 Financials**: Generics revenue grew 22% YoY to $90.3 million, driven by prucalopride (180-day exclusivity). Brands revenue increased 32% YoY to $13.2 million. Gross margin improved to 64.9% due to Rare Disease mix and Generics pricing.
- **Balance Sheet**: Cash increased to $217.8 million, with net leverage of 2.2x trailing EBITDA. Full-year EBITDA guidance raised to $213-$223 million (37%-43% growth). U.S. GAAP tax rate expected at 24%-25%.
- **Guidance Details**: Generics growth expected to moderate in H2 due to prucalopride competitors. Brands revenue to normalize post-Q2 spike. R&D spend up 130% YoY to $16 million for Cortrophin trials and retina pipeline.

**【Q&A Highlights】**
- **Cortrophin Growth Drivers**: 33% QoQ growth in ophthalmology, 15% of use in acute gout flares, and 70% new cases with prefilled syringe. Over 50% prescribers are new to ACTH, supporting multiyear growth.
- **Retina Challenges**: Medicare co-pay funding gaps persist, impacting ILUVIEN/YUTIQ. NEW DAY trial data may support earlier DME use, but 2025 guidance reflects ongoing access issues.
- **Capital Allocation**: Prioritize organic growth and Rare Disease M&A. Gross margin expected to stabilize at 63%-64% in 2025, with focus on procurement and U.S. manufacturing efficiency.
- **Tariff Position**: 90%+ U.S.-manufactured products, <5% China imports. Strong balance sheet supports inventory levels amid regulatory uncertainty.


ANI Pharmaceuticals, Inc. (ANIP) Q2 2025 Earnings Call Transcript

- **Record Q1 Growth**: $197.1M revenue (+43% YoY), driven by generics (+41%), Cortrophin Gel (+43%), and rare disease expansion.
- **2025 Guidance Raised**: $768M-$793M (25%-29% growth), EBITDA $195M-$205M, reflecting generics strength and rare disease pipeline.
- **Cortrophin Momentum**: 40% new prescribers, pre-filled syringe launch, Phase IV gout study to validate acute flare use.
- **Retina Recovery**: April demand near Q4 2024 levels, Part D pathway and label expansion for ILUVIEN/YUTIQ.
- **Generics Dominance**: Prucalopride drives mid-double-digit growth, 90% U.S.-manufactured products shield from tariffs.

**【CEO Opening Remarks】**
- Q1 2025 revenue reached $197.1 million, up 43% YoY, driven by generics, Cortrophin Gel, and Brands portfolio.
- 2025 guidance raised to $768M-$793M (25%-29% growth) and EBITDA $195M-$205M, reflecting generics strength and rare disease growth.
- Cortrophin Gel Q1 revenue $52.9M (+43% YoY), with 40% prescribers new to ACTH category, targeting multi-year growth.
- Retina products (ILUVIEN/YUTIQ) Q1 $16.1M, impacted by Medicare access challenges but April demand near Q4 2024 levels.
- Generics Q1 $98.7M (+41% YoY), Prucalopride launch driving mid-double-digit annual growth.

**【Christopher Mutz - Rare Disease Update】**
- Cortrophin Gel: Record patient starts in Q1, pre-filled syringe launched in April, Phase IV gout study planned for 2025.
- ILUVIEN/YUTIQ: U.S. challenges due to Medicare Part B funding, but April demand recovery; expanded label for chronic NIU-PS approved.
- Ophthalmology salesforce optimized, with full strength expected Q2 2025.

**【Stephen Carey - Financial Review】**
- Q1 2025 non-GAAP EPS $1.70, EBITDA $50.7M, cash $149.8M post royalty buyout.
- 2025 guidance: Generics mid-double-digit growth, Brands normalization, rare disease 34%-38% Cortrophin growth.
- Gross margin 63.1% (down 130bps YoY due to royalty mix), operating expenses up 56.5% YoY for salesforce expansion.

**【Q&A Highlights】**
- **Cortrophin Syringe Impact**: Early positive feedback, launch in April, pricing premium but limited margin impact.
- **Retina Market Recovery**: April demand near Q4 2024, Part D pathway and specialty pharmacy solutions in progress.
- **Tariff Strategy**: 90% U.S.-made products, spare capacity to capitalize on supply chain disruptions.
- **Generic Growth**: Prucalopride Q1 peak, Q2 decline expected due to inventory management.
- **Competitor Dynamics**: Category growth 16% (ANI +34%-38%, competitor +7.5%), addressable market 6x-8x current volume.

ANI Pharmaceuticals (ANIP)-9 May 25-2025 Q1 Earnings call transcript

- **Record Q4 performance**: $190.6M revenue (+45% YoY), Cortrophin Gel at $59.4M (+42% YoY)
- **2025 guidance upgrade**: $756-776M total revenue (+23-26%), Cortrophin Gel to $265-274M (+34-38%)
- **Rare Disease dominance**: 54% of 2025 revenue, ILUVIEN/YUTIQ targeting $100M+ with 6-10x patient growth
- **Generics resilience**: 12% 2024 growth, 2025 outlook for low double-digit expansion
- **Strategic investments**: $190M+ in R&D, 46-territory ophthalmology sales force, Siegfried manufacturing expansion

**【CEO Summary Section】**
- Total Q4 2024 revenue: $190.6 million (45% YoY growth, 24% organic growth)
- 2025 revenue guidance: $756-776 million (23-26% YoY growth)
- Cortrophin Gel Q4 revenue: $59.4 million (42% YoY growth)
- 2025 Cortrophin Gel forecast: $265-274 million (34-38% YoY growth)
- Generics business 2024 growth: 12%, 2025 outlook: low double-digit growth
- Alimera acquisition: ILUVIEN/YUTIQ Q4 revenue $27.6 million, 2025 target $97-103 million
- Brands portfolio Q4 revenue: $19.8 million (59% YoY growth)

**【CFO Financial Commentary】**
- Q4 2024 non-GAAP EBITDA: $50 million (65% YoY growth)
- 2025 EBITDA guidance: $190-200 million (22-28% YoY growth)
- Non-GAAP gross margin: 63.5% (up 3.9ppt YoY)
- R&D expenses: $16.2 million (68% YoY growth)
- SG&A expenses: $54.8 million (42% YoY growth)
- Net debt: $639.2 million (2.5x net leverage)

**【Q&A Key Takeaways】**
- ILUVIEN/YUTIQ market access challenges: Medicare funding delays, but <5,000 patients on therapy vs 6-10x addressable population
- Cortrophin Gel gout indication: 15% of volume, 15% of new prescribers start with gout
- Rare Disease pipeline: $190 million+ investment in prefilled syringe, NEW DAY/SYNCHRONICITY trials
- Generics growth drivers: 17 new 2024 launches, prucalopride exclusivity, low double-digit volume growth
- M&A strategy: Maintain <3x net leverage, focus on rare disease
- Supply chain: ILUVIEN manufacturing expansion on track, YUTIQ transition to Siegfried by Q2 2025

Actual												1.04	0.69	0.97	0.8	1.04	0.67	1.01	0.54	-0.12	0.13	0.64	0.76	1.17	1.28	1.27	1	1.21	1.02	1.34	1.63	1.7	1.8	2.04	2.33
Forecast												0.89	0.7467	0.8833	0.9433	0.71	0.605	0.7	0.74	0.0933	0.22	0.5525	0.672	0.352	0.6667	0.8433	0.855	0.996	0.95	1.086	1.435	1.3825	1.4057	1.7701	1.9821
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+16.85%	-7.59%	+9.82%	-15.19%	+46.48%	+10.74%	+44.29%	-27.03%	-228.62%	-40.91%	+15.84%	+13.10%	+232.39%	+91.99%	+50.60%	+16.96%	+21.49%	+7.37%	+23.39%	+13.59%	+22.97%	+28.05%	+15.25%	+17.55%

ANIP

ANIP fundamentals

ANIP Q4 2025 Earnings

Earnings Call

You can ask Aime

ANIP

ANIP fundamentals

ANIP Q4 2025 Earnings

Earnings Call

ANIP Earnings Call Summary for Q4/20258:00 AM on Feb 27, 2026

ANIP Earnings Call Summary for Q3/20258:30 AM on Nov 7, 2025

ANIP Earnings Call Summary for Q2/20258:30 AM on Aug 8, 2025

ANIP Earnings Call Summary for Q1/20258:00 AM on May 9, 2025

ANIP Earnings Call Summary for Q4/20248:00 AM on Feb 28, 2025

You can ask Aime